Abstract: The present application relates to the secondary binding site of dipeptidyl peptidase IV, its relationship amongst substrates and to the modulation of substrate specificity of dipeptidyl peptidase IV (DP IV, synonym: DPP IV, CD26, EC 3.4.14.5). The application relates further to compounds that bind to the secondary binding site of DP IV and their use to modulate the substrate specificity of DP IV; methods of treatment of various DP IV mediated disorders; and screening methods for the identification of secondary binding sites on DP IV and DP IV-like enzymes.

Abstract: Inhibitors of prolyl endopeptidase of formula 1 W—KCONH—X—CON—Y—CO—Z??(1) wherein K, W, X, Y and Z are specified in the description. The compounds are useful for the treatment of diseases such as mild cognitive impairment (MCI), Alzheimer's disease, Down Syndrome, Parkinson disease and Chorea Huntington.

Abstract: The present invention relates to novel inhibitors of prolyl endopeptidase of formula 1 W—KCONH—X—CON—Y—CO—Z??(1) wherein K, W, X, Y and Z are specified in the description. The compounds are useful for the treatment of diseases such as mild cognitive impairment (MCI), Alzheimer's disease, Down Syndrome, Parkinson disease and Chorea Huntington.

Abstract: The present invention relates to novel inhibitors of prolyl endopeptidase of formula 1 W—KCONH—X—CON—Y—CO—Z ??(1) wherein K, W, X, Y and Z are specified in the description. The compounds are useful for the treatment of diseases such as mild cognitive impairment (MCI), Alzheimer's disease, Down Syndrome, Parkinson disease and Chorea Huntington.

Abstract: The use of perfluorinated heterocyclic compounds of the general formula I, ##STR1## wherein n represents 2-8,X and Y represent a --CF.sub.2 OCF.sub.2 -- group, a --CF.sub.2 --CF.sub.2 --CF.sub.2 -- group or a --CF(CF.sub.3)--CF.sub.2 -- group, andY is a --CF.sub.2 --O--CF.sub.2 -- group, a --CF(CF.sub.3)--CF.sub.2 -- group or a --CF.sub.2 --CF.sub.2 --CF.sub.2 -- group,or mixtures thereof, is described as emulsion-stabilizing additives in medically usable aqueous emulsions of perfluorocarbons, optionally containing hetero atoms, suitable for use in blood substitutes. The compounds are obtained by electrochemical perfluorination.

Abstract: Membrane keyboards are manufactured using screen-printable, electrically conductive pastes consisting of 40 to 75% by weight of metal powder (silver, aluminum, copper and their mixtures), 5 to 55% by weight of an organic solvent and 5-20% by weight of and synthetic resin based on a thermoplastic epoxy or phenoxy resin with an average molecular weight of 10,000 to 250,000 and an epoxide content of 0 to 1.